Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

human apotransferrin

Phase 2Biologic

PProthya Biosolutions

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Congenital AtransferrinemiaActive, not recruiting

Congenital AtransferrinemiaPhase 2

Active, not recruiting

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Congenital Atransferrinemia

NCT01797055

Clinical

Trials by Indication[1]

Haemophilia B1 trial

Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)

Completed·PProthya Biosolutions·Phase 4·NCT00139828·12 enrolled

Thalassemia1 trial

Apotransferrin in Patients With β-thalassemia

Terminated·PProthya Biosolutions·Phase 2·NCT03993613·10 enrolled

Congenital Atransferrinemia1 trial

Dose Escalating Study to Evaluate Pharmacokinetics, Efficacy and Safety of Apotransferrin in Atransferrinemia Patients

Active, not recruiting·PProthya Biosolutions·Phase 2·NCT01797055·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for human apotransferrin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — human apotransferrin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for human apotransferrin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Prothya Biosolutions company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: PProthya Biosolutions

Related News